Oral metronidazole is a prescription nitroimidazole antimicrobial supplied in different U.S. dosage forms. The familiar 250 mg and 500 mg immediate-release tablets are not the same presentation as 375 mg capsules, 750 mg extended-release tablets or an oral suspension. A treatment decision involves more than the word metronidazole: the prescriber must identify an appropriate medicine, release mechanism, form and instructions for the specific situation. This page maps those oral products without recommending a dose or promising a particular brand is available.
Two details are especially easy to miss in product searches. First, extended-release tablets are engineered to release metronidazole differently from immediate-release tablets, so numbers on their labels do not establish interchangeability. Second, a liquid concentration such as LIKMEZ 500 mg per 5 mL is a measure of liquid strength, not a 500 mg solid tablet. Use our tablet product guide, 375 mg capsule guide and oral suspension overview to identify the exact family.
After a clinician establishes that oral metronidazole is appropriate, a licensed pharmacy must fill the order according to its route, dosage form and quantity. A published label or FDA approval listing cannot confirm what is in stock at a particular location. If your question is about lawful pharmacy access rather than pharmaceutical formulation, the oral metronidazole buying guide covers the steps from prescription to dispensing.
Oral route identifies how the medicine enters the body; dosage form identifies what the patient receives. An immediate-release tablet, a capsule and a liquid suspension may contain metronidazole but differ in their formulation, strength expression, packaging and product-specific instructions. A prolonged-release tablet is a separate design that should not be treated as an ordinary tablet with a larger number printed on it.
Use this table to decode prescriptions and pharmacy listings rather than infer which medicine should be prescribed. FDA approval or an appearance in DailyMed supports the existence of a labeled product, not a claim of live nationwide inventory. Product versions, marketing statuses and manufacturers can change.
| Form | Example U.S. presentation | Key distinguishing feature | Next product check |
|---|---|---|---|
| Immediate-release tablet | 250 mg | Oral solid tablet; not an ER product | Strength, imprint, prescription instructions |
| Immediate-release tablet | 500 mg | Different tablet strength; same oral route | Exact ordered tablet strength and amount |
| Capsule | 375 mg | Capsule formulation with its own labeling | Capsule identity rather than tablet substitution |
| Extended-release tablet | 750 mg ER | Modified-release formulation | ER wording, swallowing and food directions |
| Ready-to-use suspension | LIKMEZ 500 mg/5 mL | Liquid concentration rather than tablet strength | Bottle label and calibrated measuring device |
Generic oral metronidazole tablets commonly appear in 250 mg and 500 mg strengths. Strength is the amount in one tablet; it does not determine an appropriate regimen without the diagnosis and instructions on the prescription. Pharmacy descriptions should distinguish the actual oral tablet from a similarly named dermal or vaginal product. Individual tablet listings can differ by labeler, imprint and package size.
The 250 mg product page and 500 mg product page focus on strength identification. This hub does not repeat their specific label-checking steps. If the dispensed strength differs from the prescription, ask the pharmacist to verify the order rather than trying to calculate a tablet combination independently.
Metronidazole 375 mg capsules are a documented oral product family, including the FLAGYL 375 capsule label and generic capsule labels. The capsule dosage form is not simply another label for an immediate-release tablet, nor does the existence of a 375 mg capsule imply that a matching 375 mg tablet is the intended product. Capsule appearance or a historic brand name should not be used as evidence of stock.
For an order specifying capsules, the pharmacy should confirm the dosage form, strength and product identity. If tablets appear in search results instead, do not assume they are acceptable replacements because the active ingredient matches. The dedicated capsule page explains how the brand, generic label and packaged product relate.
The U.S. extended-release 750 mg formulation has a distinct label and release profile. Its product-specific directions include swallowing the tablet whole and fasting-related administration conditions. These are formulation properties, not optional preferences and not universal instructions for every metronidazole product. A larger milligram number does not imply a stronger substitute for ordinary tablets on the same schedule.
Historic Flagyl ER branding needs care because product marketing status can differ from generic label availability. Verify a particular product through current FDA records and a pharmacist, not a seller's description. Our ER 750 mg guide covers these distinctions in detail and does not claim that discontinued branded stock remains available.
LIKMEZ is a U.S.-approved ready-to-use oral suspension labeled 500 mg/5 mL. That notation represents the drug amount per volume, so the correct measured volume depends on the clinician's prescription. A calibrated oral dosing device is needed to measure liquid medicine accurately; ordinary kitchen spoons should not be used. Bottle handling and storage directions are also product-specific.
Compounded liquid metronidazole preparations may be made for specific patients under applicable compounding rules, but their existence does not mean they are FDA-approved generic equivalents to LIKMEZ. Their concentration, ingredients, stability and instructions must be verified independently. Compare oral suspension options with the LIKMEZ brand record without assuming products can be swapped freely.
Flagyl is a recognizable metronidazole name, but FDA product history differs by strength and form. In 2024 the FDA confirmed that branded FLAGYL 250 mg and 500 mg tablets belonged to the discontinued product list and were not withdrawn for reasons of safety or effectiveness. That conclusion does not remove access to appropriately approved generic tablets and says nothing about the real-time supply of a named pharmacy.
Brand-specific 375 mg capsules and the legacy ER identity also require separate verification. The FDA Orange Book can help check approval and therapeutic equivalence within a defined form and route; it should not be read as a live retailer catalog. For the broader context, review the Flagyl brand profile and the generic oral product guide.
Before a pharmacist dispenses oral metronidazole, the order must make clear the prescribed drug, oral route, strength, formulation, instructions and quantity. The prescriber can also indicate relevant clinical details or brand preferences. An electronic prescription does not remove the need for the pharmacy to evaluate the medication and confirm its appropriateness to dispense under applicable rules.
Patients can help prevent errors by comparing the drug name and dosage form on the pharmacy label with their intended prescription. If a 500 mg tablet order appears as an oral suspension or 750 mg ER listing, the discrepancy should be resolved with the pharmacist or prescriber. The prescription page explains the mechanics of this order in greater detail.
Oral metronidazole can cause adverse effects and has important interactions and precautions that require professional assessment. Labeling describes hypersensitivity, neurological events and drug interactions, including disulfiram and certain other medications. Requirements concerning alcohol or propylene glycol may also appear in product-specific labeling; do not replace the supplied instructions with generalized internet advice. Pregnancy, hepatic disease and other patient factors warrant clinical consideration.
Appropriate antimicrobial use means treating a diagnosed or strongly suspected susceptible condition rather than taking metronidazole for an undiagnosed symptom. Keep the original directions, ask about concerning reactions and obtain medical help for severe symptoms. This overview identifies form-related issues; it is not a substitute for full prescribing information.
The oral route can deliver metronidazole systemically, but the same route may be considered for different infections with different clinical priorities. An oral formulation may be discussed in connection with bacterial vaginosis, trichomoniasis or certain other susceptible infections; these contexts do not all share the same treatment approach. Diagnosis, test results where indicated, medication history and specific professional guidelines remain essential. A reader should not infer an appropriate regimen merely from the existence of 250 mg or 500 mg tablets.
The clinician may also choose a different medication or a route-specific medicine if clinical circumstances support it. For example, vaginal gel is a distinct BV product family but is not a substitute for systemic therapy in trichomoniasis. Product pages here therefore concentrate on what the pharmacy should dispense once the clinical decision has been made, rather than presenting a treatment menu to self-select.
Match the route first, then the dosage form, strength or liquid concentration, immediate-release versus extended-release status, and the quantity on the prescription. For a liquid, identify the concentration and measuring device; for a 375 mg capsule, check that the pharmacy is dispensing a capsule; for ER 750 mg, confirm the formulation-specific directions. Do not infer therapeutic equivalence from the ingredient name alone.
If a pharmacist proposes a different presentation, request an explanation and any necessary prescriber authorization. Only after the product identity is clear should you compare pickup, delivery and payment options. The oral availability guide explains how to verify actual supply without mistaking FDA records for live inventory.
Oral products include immediate-release tablets, 375 mg capsules, extended-release 750 mg tablets and an approved ready-to-use suspension. The ordered form and formulation matter in addition to the ingredient name.
They contain the same active ingredient in different tablet strengths. A patient should not change tablet strength or number without instructions from a qualified clinician or pharmacist.
An established U.S. 375 mg oral product family is capsules, including the FLAGYL 375 labeling and generic capsule products. Verify the exact dosage form on the prescription.
ER means extended release. The 750 mg tablet is designed with different release characteristics and has its own administration directions. It should not be treated as a standard immediate-release tablet.
The labeling for metronidazole ER 750 mg states that the tablets should not be split, chewed or crushed. Ask your clinician or pharmacist about swallowing concerns before making any changes.
LIKMEZ is an FDA-approved ready-to-use metronidazole oral suspension labeled 500 mg/5 mL. It is a liquid medicine with product-specific measuring instructions, not a tablet.
Not necessarily. Compounded preparations may differ in concentration, ingredients and stability; they are not automatically FDA-approved or interchangeable generic versions of LIKMEZ.
The branded 250 mg and 500 mg FLAGYL tablets appear in the FDA discontinued products list. Approved generics are a distinct issue, and current pharmacy stock must be checked directly.
No automatic substitution is appropriate. Oral and vaginal products have different labeling, exposure and clinical use. A prescriber must determine the appropriate route and treatment.
Match the prescription with the pharmacy label for active ingredient, route, dosage form, strength or concentration, ER status and quantity; ask a pharmacist to resolve discrepancies before use.